Pune-based startup InMed Prognostics Inc. has received the US Food and Drug Administration (FDA) 510(k) clearance for NeuroShield™, a fully automated brain geometry-based quantifying analytics tool/cloud platform that uses artificial intelligence (AI)/Deep Net/3D Convolutional Networks to support physicians as a clinical decision support tool for neurologists and neuroradiologists.
NeuroShield is currently in clinical use in over 220+ sites across the world. In-Med is supported by seed funding from Sriram Natarajan, Founder & CEO of Molbio Diagnostics.
NeuroShield takes 3D MR images as inputs and automatically calculates brain volumes that can assist physicians in devising treatment plans for patients with neurodegenerative diseases such as Dementia, Alzheimer's' Disease, Parkinson's, and Epilepsy. NeuroShield is the first in the world to provide reference ranges that can be adjusted to age, gender, and ethnicity, setting new standards in healthcare and bringing us closer to precision medicine that is relevant for everyone, everywhere.
